• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Gamida Cell

Kala Pharmaceuticals taps biopharma exec as chief operating officer | Personnel Moves – Nov. 27, 2017

November 27, 2017 By Sarah Faulkner

Kala Pharmaceuticals

Kala Pharmaceuticals (NSDQ:KALA) this month expanded its team of C-suite executives, naming Todd Bazemore as chief operating officer. Bazemore has spent more than 20 years in the biopharmaceutical industry, most recently working as EVP and COO for Santhera Pharmaceuticals. He has also spent time at Dyax Corp., Sunovion Pharmaceuticals, and Muro Pharmaceuticals. “We welcome Todd to […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Biogen Idec, Delcath Systems Inc., Eli Lilly & Co., Gamida Cell, Kala Pharmaceuticals, neurocrinebiosciences, pertinaxpharma, Pfizer Inc.

Gamida Cell launches severe aplastic anemia trial

August 21, 2017 By Sarah Faulkner

Gamida Cell

Gamida Cell said today that the first patient has been transplanted in a study of its CordIn product for patients with severe aplastic anemia or hypoplastic myelodysplastic syndrome. The product is designed for patients with rare genetic diseases who have no fully-matched donors for a bone marrow transplantation. Gamida Cell said it is also evaluating […]

Filed Under: Clinical Trials, Featured, Stem Cells Tagged With: Gamida Cell

Milestone Scientific appoints new CEO following FDA nod | Personnel Moves – July 13, 2017

July 13, 2017 By Sarah Faulkner

Milestone Scientific

Milestone Scientific (NYSE:MLSS) said this week that it appointed Daniel Goldberger to the company’s corner office. Leonard Osser, who previously served as CEO, is slated to remain on the board and will continue to serve as director of Milestone’s China operations. The appointment comes on the heels of the FDA’s decision to grant Milestone’s CompuFlo epidural […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AstraZeneca plc, Avalon, Biogen Idec, cingulatetherapeutics, foamixpharmaceuticals, Gamida Cell, Ipsen, mannkind, milestonescientific, Novaliq GmbH, portal instruments

Gamida Cell lands $40m for late-stage NiCord trial

June 19, 2017 By Sarah Faulkner

Gamida Cell

Gamida Cell said today that it raised $40 million to support the ongoing Phase III trial of its NiCord cell graft and expand its in-house manufacturing capacity. The private financing was led by new investor Shavit Capital. VMS Investment Group and Israel Biotech Fund joined existing investor Novartis in the round, as well as Clal Biotechnology […]

Filed Under: Clinical Trials, Featured, Funding Roundup, Stem Cells Tagged With: Gamida Cell

Study: Gamida Cell’s NiCord cell graft yields fewer infections, shorter hospital stays

April 21, 2017 By Sarah Faulkner

Gamida Cell

Gamida Cell said today that its NiCord cell graft produces fewer infections, shorter hospital stays and shorter time to engraftment compared to standard umbilical cord blood transplantation. The company’s work was published in Biology of Blood and Marrow Transplantation.  “Our results indicate that rapid hematopoietic recovery from Gamida Cell’s NiCord transplantation approach is associated with clinical benefit. […]

Filed Under: Clinical Trials, Featured, Oncology, Stem Cells Tagged With: Gamida Cell

Gamida Cell wins additional EMA orphan drug designation for NiCord

March 23, 2017 By Sarah Faulkner

Gamida Cell

Gamida Cell said today that the European Medicines Agency granted its NiCord cell graft an additional orphan drug designation as a treatment for hematopoietic stem cell transplantation, or bone marrow transplantation. The treatment is a graft derived from umbilical cord blood which has been expanded and enriched with stem and progenitor cells, according to the […]

Filed Under: Featured, Oncology, Regulatory/Compliance, Stem Cells, Wall Street Beat Tagged With: Gamida Cell

Gamida Cell touts first patient treated in Phase III NiCord trial

February 28, 2017 By Sarah Faulkner

Gamida Cell

Gamida Cell said today that the 1st patient has been treated in the Phase III registration trial of its NiCord cell graft for patients with blood cancer. The treatment is a graft derived from umbilical cord blood which has been expanded and enriched with stem and progenitor cells, according to the company. The Jerusalem-based company’s […]

Filed Under: Clinical Trials, Featured, Oncology, Research & Development Tagged With: Gamida Cell

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS